Literature DB >> 25083887

The regulation and assessment of follicular growth.

Cheryl E Dunlop1, Richard A Anderson.   

Abstract

Folliculogenesis is the process by which waves of small primordial follicles possessing immature oocytes are recruited to undergo development into large antral follicles, with one then being selected for ovulation of a fully competent oocyte. Folliculogenesis can be divided into three stages: follicle recruitment, selection and ovulation, and has two phases: the initial gonadotrophin-independent phase and the later gonadotrophin-dependent phase. It involves an elaborate array of biochemical signalling factors, both stimulatory and inhibitory, and the regulation of follicle growth relies on these being tightly controlled. Their increasing understanding allows reproductive biologists to attempt manipulation of folliculogenesis, which can be useful in clinical areas such as assisted reproduction and contraception. The rising average age of childbearing in many developed countries is bringing an additional focus on the importance of assessing a woman's non-growing follicular pool; i.e. her ovarian reserve. This review examines the important regulatory players in the different stages of folliculogenesis and describes some of the currently available measures of ovarian reserve.

Entities:  

Keywords:  Anti-Müllerian hormone; folliculogenesis; non-growing follicular pool; ovarian reserve

Mesh:

Substances:

Year:  2014        PMID: 25083887     DOI: 10.3109/00365513.2014.936674

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest Suppl        ISSN: 0085-591X


  8 in total

1.  The anti-Müllerian hormone (AMH) induces forkhead box L2 (FOXL2) expression in primary culture of human granulosa cells in vitro.

Authors:  Sandro Sacchi; Federica Marinaro; Susanna Xella; Tiziana Marsella; Daniela Tagliasacchi; Antonio La Marca
Journal:  J Assist Reprod Genet       Date:  2017-06-29       Impact factor: 3.412

2.  Effects of VEGF + Mesenchymal Stem Cells and Platelet-Rich Plasma on Inbred Rat Ovarian Functions in Cyclophosphamide-Induced Premature Ovarian Insufficiency Model.

Authors:  Birol Vural; Gokhan Duruksu; Fisun Vural; Merve Gorguc; Erdal Karaoz
Journal:  Stem Cell Rev Rep       Date:  2019-08       Impact factor: 5.739

3.  Ovarian function following targeted anti-angiogenic therapy with bevacizumab.

Authors:  Atsushi Imai; Satoshi Ichigo; Kazutoshi Matsunami; Hiroshi Takagi; Ichiro Kawabata
Journal:  Mol Clin Oncol       Date:  2017-05-05

4.  Co-transplantation of Human Ovarian Tissue with Engineered Endothelial Cells: A Cell-based Strategy Combining Accelerated Perfusion with Direct Paracrine Delivery.

Authors:  Limor Man; Laura Park; Richard Bodine; Michael Ginsberg; Nikica Zaninovic; Glenn Schattman; Robert E Schwartz; Zev Rosenwaks; Daylon James
Journal:  J Vis Exp       Date:  2018-05-16       Impact factor: 1.355

5.  Engineered endothelium provides angiogenic and paracrine stimulus to grafted human ovarian tissue.

Authors:  Limor Man; Laura Park; Richard Bodine; Michael Ginsberg; Nikica Zaninovic; Omar Alexander Man; Glenn Schattman; Zev Rosenwaks; Daylon James
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

6.  Further characterization of adult sheep ovarian stem cells and their involvement in neo-oogenesis and follicle assembly.

Authors:  Hiren Patel; Deepa Bhartiya; Seema Parte
Journal:  J Ovarian Res       Date:  2018-01-05       Impact factor: 4.234

7.  A single-cell atlas of the cycling murine ovary.

Authors:  Mary E Morris; Marie-Charlotte Meinsohn; Maeva Chauvin; Hatice D Saatcioglu; Aki Kashiwagi; Natalie A Sicher; Ngoc Nguyen; Selena Yuan; Rhian Stavely; Minsuk Hyun; Patricia K Donahoe; Bernardo L Sabatini; David Pépin
Journal:  Elife       Date:  2022-10-07       Impact factor: 8.713

8.  Pharmacological inhibition of the PI3K/PTEN/Akt and mTOR signalling pathways limits follicle activation induced by ovarian cryopreservation and in vitro culture.

Authors:  Carmen Terren; Michelle Nisolle; Carine Munaut
Journal:  J Ovarian Res       Date:  2021-07-19       Impact factor: 4.234

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.